Open access · CC-BY
via OpenAlex
Klotho and FGF23: endocrine regulation of kidney disease outcomes
O.I. Nishkumay, Mike KS Chan, Oleg B. Iaremenko, В.Е. Кондратюк, I. Rudenko, O. E. Zaytseva, O.I. Rokyta, Ganna Mykytenko
INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · 2026
Abstract
Endocrine regulation of mineral metabolism largely depends on the interaction between the kidneys, bone tissue, and parathyroid glands. One of the key regulators of this axis is the Klotho-fibroblast growth factor 23 (FGF23) system, which plays a central role in the control of phosphate and vitamin D homeostasis. The α-Klotho protein, predominantly expressed in the renal tubules, functions as an essential co-receptor for FGF23, enabling its binding to fibroblast growth factor receptors and activation of downstream signaling pathways in target cells. Disruption of this signaling system, particularly in chronic kidney disease, leads to disturbances in phosphate and calcium metabolism, vascular calcification, renal fibrosis, and cardiovascular complications. In addition to its role in FGF23 signaling, soluble Klotho exhibits multiple systemic protective properties, including antioxidant, anti-inflammatory, anti-fibrotic, and cytoprotective effects. A growing body of experimental and clinical evidence suggests that reduced circulating and renal Klotho levels may serve as an early biomarker of kidney dysfunction and are associated with adverse renal and cardiovascular outcomes. Conversely, restoration of Klotho levels — either through administration of recombinant protein or therapeutic strategies aimed at enhancing endogenous expression — has demonstrated promising renoprotective and cardioprotective effects in experimental models. Overall, the Klotho-FGF23 axis represents a crucial endocrine regulator of kidney disease progression and its systemic complications. Further studies are required to better understand the molecular mechanisms underlying this pathway and to translate these findings into novel diagnostic markers and targeted therapeutic strategies for kidney diseases.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.22141/2224-0721.22.3.2026.1715
- Canonical
- link ↗
- Fetched
- 2026-10-26 MST
Cite this
APA
Nishkumay, O., Chan, M.K., Iaremenko, O.B., Кондратюк, �., Rudenko, I., Zaytseva, O.E., Rokyta, O., & Mykytenko, G. (2026). Klotho and FGF23: endocrine regulation of kidney disease outcomes. <em>INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)</em>. https://doi.org/10.22141/2224-0721.22.3.2026.1715
Vancouver
Nishkumay O, Chan MK, Iaremenko OB, Кондратюк �, Rudenko I, Zaytseva OE, et al. Klotho and FGF23: endocrine regulation of kidney disease outcomes. INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine). 2026. doi:10.22141/2224-0721.22.3.2026.1715.
BibTeX
@article{oi2026Klotho,
title = {Klotho and FGF23: endocrine regulation of kidney disease outcomes},
author = {O.I. Nishkumay and Mike KS Chan and Oleg B. Iaremenko and В.Е. Кондратюк and I. Rudenko and O. E. Zaytseva and O.I. Rokyta and Ganna Mykytenko},
journal = {INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)},
year = {2026},
doi = {10.22141/2224-0721.22.3.2026.1715},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Aging 2022
Open access · CC-BY
Pathobiology of the Klotho Antiaging Protein and Therapeutic Considerations
Journal of the Pakistan Medical Association 2026
Open access · CC-BY
Klotho and The Kidney
Biomolecules 2026
Open access · OA
Emerging Roles of FGFR3 and FGF23-Associated Signaling in Renal Fibrosis: Molecular Integration, Clinical Correlates, and Therapeutic Perspectives.
JPMA. The Journal of the Pakistan Medical Association 2026
Citation only
Klotho and The Kidney.
Toxins 2020
Open access · CC-BY
Klotho/FGF23 and Wnt Signaling as Important Players in the Comorbidities Associated with Chronic Kidney Disease
Frontiers in Endocrinology 2018
Open access · CC-BY